Precision Biosciences (DTIL) Cash from Operations (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Cash from Operations data on file, last reported at 11937000.0 in Q1 2026.

• Cash from Operations for Q1 2026 came in at 11937000.0, up 37.35% year-over-year; the trailing twelve-month figure through Mar 2026 was 58728000.0 (changed 0.36% YoY), and the FY2025 annual result was 65843000.0, down 12.66% from the prior year.
• Cash from Operations eased to 11937000.0 in Q1 2026 per DTIL's latest filing, from 11250000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 29186000.0 in Q3 2022 and troughed at 31464000.0 in Q1 2023.
• A 5-year average of 15652470.59 and a median of 18981000.0 in 2024 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations surged 222.09% in 2022, then slumped 179.12% in 2023.
• A 5-year view of Cash from Operations shows it stood at 21843000.0 in 2022, then surged by 61.44% to 8423000.0 in 2023, then plunged by 121.81% to 18683000.0 in 2024, then surged by 39.78% to 11250000.0 in 2025, then retreated by 6.11% to 11937000.0 in 2026.
• Business Quant data shows DTIL's Cash from Operations at 11937000.0 in Q1 2026, 11250000.0 in Q4 2025, and 15270000.0 in Q3 2025.